IDH inhibitors are a class of targeted cancer therapies designed to block the activity of mutant isocitrate dehydrogenase (IDH) enzymes. Mutations in IDH1 and IDH2 genes are found in various cancers, including gliomas, acute myeloid leukemia (AML), and cholangiocarcinoma. These mutations result in the production of an oncometabolite, 2-hydroxyglutarate (2-HG), which disrupts normal cellular functions and promotes tumor growth.
